Tariffs become structural

U.S. tariffs are no longer landing as one-off threats; they are being built into standing rules for chips, medicines and other strategic goods. (whitehouse.gov) President Donald Trump issued Proclamation 11002 on January 14, 2026, after a Section 232 national-security investigation, imposing a 25% tariff on semiconductors, semiconductor manufacturing equipment and some derivative products. The White House said the measure covers certain advanced computing chips, including Nvidia H200 and AMD MI325X models. (federalregister.gov (whitehouse.gov) A House of Commons Library briefing says the January 14 action also put a 25% tariff on specific semiconductors re-exported to China, adding another layer beyond the tariff paid when goods first enter the United States. U.S. Customs and Border Protection said in a January 2026 tariff overview that importers must calculate duties under the exact language of proclamations, tariff schedules and Federal Register notices. (commonslibrary.parliament.uk) (cbp.gov) Section 232 is the law the administration is using to treat imports as a national-security issue rather than a normal trade dispute. The semiconductor proclamation says Commerce found U.S. production capacity was too small to meet domestic demand and that defense systems depend on high-performance chips for radar, communications and guidance. (federalregister.gov) (whitehouse.gov) The same framework is now reaching drug supply chains. Commerce opened a Section 232 investigation into pharmaceuticals and pharmaceutical ingredients on April 1, 2025, covering finished drugs, medical countermeasures, active pharmaceutical ingredients and key starting materials. (federalregister.gov) That probe turned into tariffs on April 2, 2026, when Trump issued Proclamation 11020. The White House said patented pharmaceutical products and ingredients would face a 100% tariff, while generic pharmaceuticals and their associated ingredients were excluded “at this time,” and the proclamation set 120-day and 180-day phase-in periods for different companies. (federalregister.gov) (whitehouse.gov) The result is a trade system where the tariff rate depends not just on what a product is, but where it was made, whether it was re-exported, and whether Washington classifies the sector as strategic. The United States Trade Representative’s tariff-action page now lists separate tracks under Section 232 and other authorities, showing how tariff policy has spread across multiple legal channels. (ustr.gov) (cbp.gov) Britain’s parliament described the shift in practical terms for exporters: pharmaceuticals can enter the United States tariff-free under a new U.K.-U.S. arrangement, while future exemptions for semiconductors remain only a possibility tied to negotiations. That leaves firms sorting products by sector, destination and supply-chain status before they can price a shipment. (commonslibrary.parliament.uk) The White House says the tariffs are meant to rebuild domestic capacity in sectors it calls essential to economic and military strength. For companies moving chips and medicines across borders, the immediate change is simpler: tariffs are becoming part of the operating map, not just a bargaining tactic. (whitehouse.gov 1) (whitehouse.gov 2)